Tocilizumab for severe COVID-19: a systematic review and meta-analysis

Review (7 studies; n= 592) found no significant differences in all-cause mortality (16.3% vs. 24.1%; RR = 0.62; 0.31–1.22); risk of ICU admission (35.0% vs. 15.8%; 1.51; 0.33–6.78) and mechanical ventilation (32.4% vs. 28.6%; 0.82; 0.14–4.94) between tocilizumab and controls.

Source:

International Journal of Antimicrobial Agents